Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis
about
A holistic approach to targeting disease with polymeric nanoparticlesStealth Properties to Improve Therapeutic Efficacy of Drug NanocarriersCFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisDendrimer-Based Selective Proteostasis-Inhibition Strategy to Control NSCLC Growth and ProgressionSynthesis, characterization, and in vitro activity against Candida spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid)Biodegradable nanoparticles of mPEG-PLGA-PLL triblock copolymers as novel non-viral vectors for improving siRNA delivery and gene silencing.Nanotechnology approaches for inhalation treatment of fibrosis.Rescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitorsPEGylation of cationic, shell-crosslinked-knedel-like nanoparticles modulates inflammation and enhances cellular uptake in the lung.Microtubule targeted therapeutics loaded polymeric assembled nanospheres for potentiation of antineoplastic activity.Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseasesChallenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.Nanotherapeutics for Alzheimer's disease (AD): Past, present and future.Nanoparticles as delivery carriers for anticancer prodrugs.Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand?Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol.Nano-based rescue of dysfunctional autophagy in chronic obstructive lung diseases.Facile Synthesis of PEGylated PLGA Nanoparticles Encapsulating Doxorubicin and its In Vitro Evaluation as Potent Drug Delivery Vehicle.Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite.Dendrimer-based selective autophagy-induction rescues ΔF508-CFTR and inhibits Pseudomonas aeruginosa infection in cystic fibrosis.Shape dependent cytotoxicity of PLGA-PEG nanoparticles on human cells.Modulation of proinflammatory activity by the engineered cationic antimicrobial peptide WLBU-2.Novel green synthesis of gold nanoparticles using Citrullus lanatus rind and investigation of proteasome inhibitory activity, antibacterial, and antioxidant potentialIn vivo fate tracking of degradable nanoparticles for lung gene transfer using PET and Ĉerenkov imaging.Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential.Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis.
P2860
Q26865163-4FE6F273-C058-4948-8F20-D69906BCD952Q27496024-AD6ACA09-FCF4-406D-A8AC-1DD55918B8FFQ28073996-D442D732-FCEF-4C1C-B331-F8D5E55124E2Q28552714-3A29A278-DFA5-479C-8FD7-5B7C5F84AFE4Q33719218-AC98E519-114D-486F-A9DD-DA95DB2F0B5DQ34152538-EFCA2235-FA3F-4E82-BCA7-240C1AEB5BD2Q34449624-46FC5CC6-A93B-47D8-909E-5C7B065008A3Q34532897-8C9F490A-C0CD-4E73-9C2B-34BB182FA91DQ34604942-DF6B99F2-29C5-4B98-B6E0-ABC72591A72CQ35893673-C42C94C3-0D07-434A-BA98-6E31BD09F2B2Q37078082-31454D35-2E42-4682-9AA8-9EEBE7AEF8C3Q37849777-20CAC7FB-7C09-46AE-BE5D-2B871E50F691Q37948993-11CE67D5-4B3C-4337-9B2A-DFC5F4017DDBQ38002956-F30343D7-899C-4F90-9DCB-6DC47A563196Q38340865-BD505185-FA29-43D4-8E3E-4FE8FF3D14F0Q38716544-B7BDAA01-F0DA-4995-B376-198FF700150FQ38937131-59E7940D-BE3D-4F0E-B1E7-BB46EC3A1F74Q39115464-C0A3E256-FCFF-4AC2-8B4D-3A71076D2345Q39343784-124BB332-6D5D-4BE0-96FF-A9D5375BFA1CQ40048899-9EC07458-BBD8-4D7B-AA40-4B37DCCA0533Q41260008-1A088A53-0188-4115-9418-C42CEADF172EQ41877292-07BD6F0C-5A67-490B-8EB4-1B90E51B5929Q42034676-43C7FE75-0D0B-44BE-8F5F-4BA826EF86B6Q42176591-3A798E6B-D1FC-4FC7-99EB-BBA63BC1BF98Q42873072-99813D6F-E9F1-468C-A1A6-3D3E8777015DQ46847846-04E6F09A-D535-4993-B42E-9F1EEE04099EQ50069018-4DF64887-5229-4990-B822-D34161BD5A7E
P2860
Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Development of PEGylated PLGA ...... ug delivery in cystic fibrosis
@ast
Development of PEGylated PLGA ...... ug delivery in cystic fibrosis
@en
Development of PEGylated PLGA ...... ug delivery in cystic fibrosis
@nl
type
label
Development of PEGylated PLGA ...... ug delivery in cystic fibrosis
@ast
Development of PEGylated PLGA ...... ug delivery in cystic fibrosis
@en
Development of PEGylated PLGA ...... ug delivery in cystic fibrosis
@nl
prefLabel
Development of PEGylated PLGA ...... ug delivery in cystic fibrosis
@ast
Development of PEGylated PLGA ...... ug delivery in cystic fibrosis
@en
Development of PEGylated PLGA ...... ug delivery in cystic fibrosis
@nl
P2093
P2860
P921
P356
P1476
Development of PEGylated PLGA ...... ug delivery in cystic fibrosis
@en
P2093
Christopher N Belcher
Indrajit Roy
Ken-Tye Yong
Neeraj Vij
Rhul Marasigan
Steven Mazur
Taehong Min
P2860
P2888
P356
10.1186/1477-3155-8-22
P577
2010-09-24T00:00:00Z
P5875
P6179
1033829332